Should we offer preventive treatment to all carriers of PLN p.(Arg14del) variant? : Pro: Provide pre-emptive treatment to asymptomatic carriers.

Authors:
de Boer RA.

Journal:
Neth Heart J

Publication Year: 2023

DOI:
10.1007/s12471-023-01793-0

PMCID:
PMC10400733

PMID:
37493902

View on PubMed View on PMC View Publisher

Journal Information

Full Title: Neth Heart J

Abbreviation: Neth Heart J

Country: Unknown

Publisher: Unknown

Language: N/A

Publication Details

Subject Category: Cardiac & Cardiovascular Systems

Available in Europe PMC: Yes

Available in PMC: Yes

PDF Available: No

Related Papers from Same Journal

View All Papers from This Journal

Transparency Score

3/6

50.0% Transparent

Transparency Indicators

Click on green indicators to view evidence text

Core Indicators

Data Sharing

Code Sharing

COI Disclosure

Evidence found in paper:

"Conflict of interest Dr. De Boer has received research grants and/or fees from AstraZeneca, Abbott, Boehringer Ingelheim, Cardior Pharmaceuticals GmbH, Ionis Pharmaceuticals, Inc., Novo Nordisk, and Roche; and has had speaker engagements with Abbott, AstraZeneca, Bayer, Bristol Myers Squibb, Novartis, and Roche."

Funding Disclosure

Evidence found in paper:

"Conflict of interest: Dr. De Boer has received research grants and/or fees from AstraZeneca, Abbott, Boehringer Ingelheim, Cardior Pharmaceuticals GmbH, Ionis Pharmaceuticals, Inc., Novo Nordisk, and Roche; and has had speaker engagements with Abbott, AstraZeneca, Bayer, Bristol Myers Squibb, Novartis, and Roche."

Protocol Registration

Open Access

Paper is freely available to read

Additional Indicators

Replication

Novelty Statement

Assessment Info

Tool: rtransparent

OST Version: N/A

Last Updated: Aug 05, 2025